What is Insulet's fair value measurement disclosure?

Insulet (PODD) reported fair value measurement disclosure of $973.6M in Q1 2026.

What is the long-term trend for Insulet's fair value measurement disclosure?

Over 2 years (2023 to 2025), Insulet's fair value measurement disclosure has grown at a 1511.0% compound annual growth rate (CAGR), from $3.8M to $986.2M.

Insulet PODD Fair Value Measurement Disclosure

Fair Value Measurement Disclosure at other companies

MedtronicMDT

——

ViatrisVTRS

——

Other financials

Income statement

See full

Revenue$761.7M+33.9%

Gross profit$529.0M+29.3%

Operating income$122.1M+37.5%

Net income$91.1M+157%

EPS (diluted)$1.30+160%

Balance sheet

See full

Cash & equivalents$480.4M-62.6%

Total debt$969.7M-45.5%

Total equity$1.3B-2.1%

Total assets$3.0B-15.1%

Cash flow

See full

Operating cash flow$113.8M+78.4%

CapEx$24.3M+97.6%

Free cash flow$89.5M+73.8%

Valuation

See full

Market cap$10.1B-19.9%

Enterprise value$10.59B-19.4%

P/E33.3×+2.0×

P/S3.5×-2.3×

Profitability

See full

Gross margin71%+0.6pp

Operating margin17.5%+2.0pp

Net margin10.4%-7.9pp

FCF margin14.3%+1.1pp

Returns & leverage

See full

Return on equity23%-14.9pp

Debt / equity0.7×-0.6×

Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:FinancialLiabilitiesFairValueDisclosure.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's fair value measurement disclosure.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Insulet's fair value measurement disclosure?: Insulet (PODD) reported fair value measurement disclosure of $973.6M in Q1 2026.
What is the long-term trend for Insulet's fair value measurement disclosure?: Over 2 years (2023 to 2025), Insulet's fair value measurement disclosure has grown at a 1511.0% compound annual growth rate (CAGR), from $3.8M to $986.2M.